NASDAQ:FOLD
Amicus Therapeutics Stock News
$11.78
-0.0800 (-0.675%)
At Close: Mar 28, 2024
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
07:00am, Friday, 01'st Mar 2024
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
12:26pm, Thursday, 29'th Feb 2024
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.
Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
10:05am, Thursday, 29'th Feb 2024
Amicus Therapeutics should deliver strong topline growth with expanding margins and increasing cash flows in 2024.
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
09:20am, Wednesday, 28'th Feb 2024
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.19 per share a year ago.
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
07:00am, Thursday, 15'th Feb 2024
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 202
Time to buy these 3 healthcare companies that raised revenue guidance?
09:00am, Tuesday, 16'th Jan 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Companies can usually gauge if their previous forecasts were in line or need to be adjusted to warn or prepare invest
Amicus (FOLD) Issues Preliminary Revenue Results for FY23
11:23am, Monday, 08'th Jan 2024
Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
11:16am, Friday, 29'th Dec 2023
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential.
Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated
02:17pm, Thursday, 09'th Nov 2023
Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates.
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
07:00am, Wednesday, 01'st Nov 2023
PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i
Amicus Therapeutics: The Right Play Now
12:24pm, Tuesday, 31'st Oct 2023
Amicus Therapeutics, Inc. is a commercial-stage biotech company focused on developing therapies for rare diseases. The company recently received FDA approval for its combination therapy Pombiliti + Op
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
07:00am, Friday, 27'th Oct 2023
PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023
Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug
10:31am, Friday, 29'th Sep 2023
Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.
3 Stocks Worth a Watch for Solid Earnings Acceleration
08:16am, Wednesday, 20'th Sep 2023
Some of the notable companies to have witnessed solid earnings acceleration as of now are Amicus Therapeutics (FOLD), Genius Sports (GENI) and Viad (VVI).
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
07:00am, Friday, 01'st Sep 2023
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in